author-photo

Anne-Gaëlle Dosne

Janssen Pharmaceutica

7

Papers

28

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.

2021 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

2019 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (4)
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies

2019 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (3)
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (21)